Insider · CIK 0001592848
Marilyn R. Carlson
Files at EVOK (Evoke Pharma Inc). First filing -, latest -.
In brief
Marilyn R. Carlson files SEC Form 4 as officer at EVOK (Evoke Pharma Inc). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Marilyn R. Carlson has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 16, 2025 | EVOK Evoke Pharma Inc | UTender of shares Common Stock | -360 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | EVOK Evoke Pharma Inc | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,291 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | EVOK Evoke Pharma Inc | DDisposition to issuer Stock Option (Right to Buy)derivative | -11,000 | - | - | 0 | Dec 17, 2025 |
| Jan 28, 2025 | EVOK Evoke Pharma Inc | AGrant or award Stock Option (Right to Buy)derivative | +11,000 | $0.00 | $0 | 11,000 | Jan 29, 2025 |
Questions about Marilyn R. Carlson
Answered from the filings on this page, as of the latest one.
Is Marilyn R. Carlson buying or selling?
Marilyn R. Carlson has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Marilyn R. Carlson's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Marilyn R. Carlson has 0.
Where does Marilyn R. Carlson file Form 4?
Marilyn R. Carlson has filed Form 4 at EVOK (Evoke Pharma Inc) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.